MYDGF抗体—艾普蒂 新品

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-4: 293T and K562 cell, Human between peritoneal stromal sarcoma tissue, HEPG2 cell lysates, Primary antibody: P06448(MYDGF Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 6 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06448(MYDGF Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

MYDGF (Myeloid-Derived Growth Factor), also known as C19orf10. is a secreted protein initially identified in bone marrow-derived myeloid cells. It is encoded by the MYDGF gene located on human chromosome 19q13.12. Structurally, it contains a conserved domain with homology to the saposin-like protein family, which is involved in lipid binding and membrane interactions. MYDGF is produced by monocytes, macrophages, and other myeloid lineage cells, functioning as a paracrine signaling molecule in tissue repair and inflammation regulation.

Research highlights MYDGF's role in promoting angiogenesis, cell survival, and tissue regeneration. In ischemic conditions, such as myocardial infarction, MYDGF enhances cardiomyocyte survival and reduces fibrosis by activating PI3K/AKT and STAT3 signaling pathways. It also stimulates endothelial cell migration and blood vessel formation, critical for post-ischemic recovery. Additionally, MYDGF exhibits anti-inflammatory effects by modulating macrophage polarization toward a pro-repair phenotype.

MYDGF antibodies are essential tools for detecting endogenous MYDGF expression in immunoassays (e.g., Western blot, ELISA, immunohistochemistry) and studying its spatial-temporal distribution in tissues. They enable investigations into MYDGF's diagnostic or prognostic value in cardiovascular diseases, metabolic disorders, and cancers. Some studies suggest MYDGF overexpression correlates with tumor progression, making it a potential therapeutic target. Commercial antibodies are typically raised against specific epitopes of human MYDGF, with cross-reactivity validated in mouse and rat models due to high sequence homology. Ongoing research focuses on clarifying its receptor interactions and therapeutic applications in regenerative medicine.